



Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Morristown, New Jersey, April 3, 2024 – Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile. Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression ([NCT06342310](https://clinicaltrials.gov/ct2/show/study/NCT06342310)).

Details of the presentations are as follows:

Podium Presentation

Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum Depression

Date: Friday, April 12, 2024

Time: 4:00-5:00 p.m. ET

Location: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor Level

Presenter: Dr. Robert Alexander, Chief Medical Officer of Reunion

Poster Presentation

Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum Depression

Session Date: Saturday, April 13, 2024

Session Time: 3:45-5:15 p.m. ET

Poster #: S150

Location: Westin Boston Seaport District: Grand Ballroom, Concourse Level

The poster will be available on Reunion’s [website](#) on Friday, April 12, 2024.

About Reunion Neuroscience Inc.

Reunion Neuroscience is committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for postpartum depression (PPD) and other underserved mental health disorders. The Company's lead asset, RE104, a proprietary, potential best-in-class, serotonergic psychedelic compound and the only 4-OH-DIPT prodrug in clinical development, is being evaluated as a potential treatment for postpartum depression, ([NCT06342310](#)), that could provide rapid symptom relief and durable efficacy. Reunion is actively investigating the use of RE104, which has a patent granted for exclusive rights for the composition of matter through 2042, in additional indications susceptible to being treated with a 5HT2A agonist molecule.

For more information about the company, visit <https://reunionneuro.com>.

Contact

Sarah Sutton, Argot Partners
(518) 932-3680
sarah@argotpartners.com